In today’s COVID-19 environment, more than ever, the myMatrixx team understands how to innovate and adapt to the changing workforce conditions. Our mission, to provide you with the highest level of customized service, has never been more important. We care deeply about our partners and their injured workers, and we are committed to providing you with the comprehensive information and resources you need to make decisions to support and grow your business.
Please use this resource to stay informed on how myMatrixx is addressing COVID-19 and check in often, as this page is updated frequently.
Image
COVID-19 Helpful Resources
Learn what the Coronavirus is, how it started, symptoms, prevention, and more:
COVID-19 Position Paper
myMatrixx View on COVID-19 Vaccination and Workers' Compensation Coverage
Cliff Belliveau and Phil Walls Featured in R&I Insights Email
June 11, 2021
The COVID-19 pandemic will continue to have an impact on workers’ compensation pharmacy for the foreseeable future. Recently, myMatrixx Vice President of Business Intelligence, Cliff Belliveau, joined Chief Clinical Officer, Phil Walls, to discuss this new landscape for industry publication Risk & Insurance’s Insights feature.
Learn more
Phil Walls Featured in WorkCompWire on Long-term Effects of the Pandemic
June 01, 2021
In a new post for industry publication WorkCompWire, myMatrixx Chief Clinical Officer Phil Walls shares how the COVID-19 pandemic will have a lasting effect on workers’ compensation pharmacy.
Learn more
Webinar Recap: “From ‘Closed for Business’ to ‘Open for Resilience,’” Featuring Mike Cirillo
May 28, 2021
On May 26, myMatrixx President and CEO Mike Cirillo joined a panel of industry leaders as part of the National Workers’ Compensation and Disability Conference’s (NWCDC) ongoing Digital Sessions Series.
Learn more
Upcoming NWCDC Panel to Feature myMatrixx President Mike Cirillo
May 17, 2021
In an upcoming webcast for the National Workers' Compensation and Disability Conference (NWCDC,) myMatrixx President, Mike Cirillo, will be a featured speaker along with other leaders in the field.
Learn more
myMatrixx Experts Featured in Industry Publications After Release of 2020 Drug Trend Report
May 10, 2021
In articles for industry publications WCI Weekly and WorkersCompensation.com, myMatrixx experts highlighted some of the key takeaways from the newly released 2020 Drug Trend Report.
Learn more
Kloxxado Receives FDA Approval for Opioid Overdoses
April 30, 2021
The U.S. Food and Drug Administration (FDA) approved Kloxxado™ (naloxone) nasal spray, 8mg, on April 29, 2021.
Learn more
myMatrixx Keeps Pressure on Spending and Identifies Key COVID-Related Effects in 2020 Drug Trend Report
April 28, 2021
In the wake of an unprecedented year for workers’ compensation pharmacy, myMatrixx was able to achieve positive outcomes, according to the newly released 2020 Drug Trend Report.
Learn more
Three Drugs on the Horizon to Watch in Workers’ Comp Pharmacy
April 21, 2021
As we continue to move into 2021, two of the biggest concerns in workers’ compensation pharmaceuticals remain the ongoing COVID-19 pandemic and the opioid misuse crisis.
Learn more